Skip to main content

ENDO: Novel Male Contraceptive Gel May Achieve Faster Sperm Suppression

Medically reviewed by Carmen Pope, BPharm. Last updated on June 12, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, June 12, 2024 -- A novel male contraceptive gel suppresses sperm production faster than other hormone-based methods for male birth control, according to a phase 2 study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston.

Danielle Gross, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health in Bethesda, Maryland, and colleagues assessed the time to sperm suppression (concentration ≤1 million/mL) with daily self-administration of segesterone acetate (8 mg)/testosterone (74 mg) combination gel in 222 healthy men.

The researchers found that 86 percent of participants achieved suppression to ≤1 million/mL during treatment. One in five participants (21 percent) were suppressed to ≤1 million/mL at five weeks, which increased to 52 percent by eight weeks and 64 percent by nine weeks. The median time for those achieving suppression was eight weeks, with 82 percent suppressed within 12 weeks and 86 percent at 15 weeks of initiating treatment.

"The development of a safe, highly effective and reliably reversible contraceptive method for men is an unmet need," senior author Diana Blithe, Ph.D., also of the National Institutes of Health, said in a statement. "While studies have shown that some hormonal agents may be effective for male contraception, the slow onset of spermatogenic suppression is a limitation."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Survival Improves With Open Hysterectomy for Cervical Cancer

FRIDAY, June 28, 2024 -- For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally invasive versus open radical...

Precision-Guided Treatment Improves Outcomes for High-Risk Pediatric Cancer

FRIDAY, June 28, 2024 -- Precision-guided treatment improves outcomes for children with high-risk cancer, according to a study published online June 6 in Nature Medicine. Loretta...

Recommendations Issued for Advanced Imaging for Pediatric Patients in ED

THURSDAY, June 27, 2024 -- In a policy statement issued by the American Academy of Pediatrics and published online June 27 in Pediatrics, recommendations are presented for...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.